COVID-19 in Parkinson’s disease: what holds the key?
Case control study with 39 COVID+ and 172 COVID- Parkinson's disease patients in Spain, showing positive and severe cases being less likely to use vitamin D supplementation compared to negative or mild/negative cases respectively. These differences were not statistically significant.
risk of severe case, 32.7% lower, OR 0.67, p = 0.45, treatment 5 of 29 (17.2%) cases,
43 of 182 (23.6%) controls, NNT 23, case control OR.
risk of case, 43.7% lower, OR 0.56, p = 0.23, treatment 6 of 39 (15.4%) cases,
42 of 172 (24.4%) controls, NNT 13, case control OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sainz-Amo et al., 24 Oct 2020, retrospective, Spain, peer-reviewed, mean age 74.5, 13 authors, dosage not specified.
Abstract: Journal of Neurology (2021) 268:2666–2670
COVID‑19 in Parkinson’s disease: what holds the key?
R. Sainz‑Amo1 · B. Baena‑Álvarez1 · I. Pareés1 · G. Sánchez‑Díez1 · P. Pérez‑Torre1 · J. L. López‑Sendón1 ·
S. Fanjul‑Arbos1 · E. Monreal1 · I. Corral‑Corral1 · N. García‑Barragán1 · J. C. Martínez‑Castrillo1 · A. Fasano2,3 ·
Received: 10 September 2020 / Revised: 4 October 2020 / Accepted: 10 October 2020 / Published online: 24 October 2020
© Springer-Verlag GmbH Germany, part of Springer Nature 2020
Introduction Parkinson’s disease (PD) is more frequent in the elderly and increases the risk of respiratory infections. Previous data on PD and SARS-CoV-2 are scarce, suggesting a poor prognosis in advanced disease and second-line therapies.
Methods A retrospective case–control study comparing patients with PD and COVID-19 and patients with PD without
COVID-19 was conducted during the pandemic period in Spain (March 1st–July 31st 2020) in a tertiary university hospital.
Results Thirty-nine (COVID-19 +) and 172 (COVID-19-) PD patients were included. Fifty-nine percent were males in
both groups, with similar age (75.9 ± 9.0 COVID-19 + , 73.9 ± 10.0 COVID-19-), disease duration (8.9 ± 6.2 COVID-19 + ,
8.5 ± 5.6 COVID-19-) and PD treatments. COVID-19 was mild in 10 (26%), required admission in 21 (54%) and caused death
in 8 (21%) patients. Dementia was the only comorbidity more frequent in COVID-19 + patients (36% vs. 14%, p = 0.0013).
However, in a multivariate analysis, institutionalization was the only variable associated with COVID-19 + (OR 17.0, 95%
CI 5.0–60.0, p < 0.001). When considering severe COVID-19 (admission or death) vs. mild or absent COVID-19, institutionalization, neoplasm, dementia and a lower frequency of dopamine agonists were associated with severe COVID-19.
In multivariate analysis, only institutionalization [OR 5.17, 95% CI 1.57–17, p = 0.004] and neoplasm [OR 8.0, 95%CI
1.27–49.8, p = 0.027] remained significantly associated.
Conclusion In our experience, institutionalization and oncologic comorbidity, rather than PD-related variables, increased
the risk of developing COVID-19, and impacted on its severity. These findings suggest that epidemiologic factors and frailty
are key factors for COVID-19 morbidity/mortality in PD. Appropriate preventive strategies should be implemented in institutionalized patients to prevent infection and improve prognosis.
Keywords SARS-CoV-2 · COVID-19 · Parkinson · Institutionalization · Comorbidity · Prognosis
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.